US life sciences venture firm OrbiMed has led a $41.4 million Series B round of financing in Turnstone Biologics, a Canada-based developer of immunotherapies for cancer.
Tag Archives | biopharma
Start-up CStone has wrapped up its first fundraising and named a new chief executive, Frank Jiang, to lead its investment strategy and development.
The latest funding will be used to help Ginkgo take its synthetic biology technology into new markets, including human health.
The raise includes new investment from Rock Springs Capital, Invesco Asset Management and Health for Life Capital, alongside existing investor PureTech.
Life Sciences Partners’ fifth vehicle easily surpassed its initial $170 million target and has already invested around a third of the proceeds in nine investments.
The life science and venture capital firm hit its target for the fund.
The proceeds of the Series A round will go towards Agenovir’s development of drugs to tackle superbugs.
The Series B funding round will be used to source therapeutic and agriculture applications for Caribou’s innovative gene editing research.
PAI will aim to support the French speciality pharma firm’s international expansion
Column Group III, which launched in February, has surpassed its $500m target through the main vehicle and a parallel fund, and will invest in biopharmaceuticals, vaccinations and other therapeutics.